Moberg Pharma launches innovative new Kerasal product in the U.S.

STOCKHOLM, February 13, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that
it shipped opening orders of its new line extension, Kerasal® Complete Care in
Walgreens, the #1 drug chain in the U.S., with additional retailers expected to
follow.
Kerasal® Complete Care, a unique new foot care product brings together two
highly effective treatments to restore healthy nail appearance and treat toe and
foot skin fungus (athlete’s foot) in a convenient dual-pack.  Targeted toward
the multitudes of consumers who have both damaged nails and toe and foot skin
fungus, Kerasal Complete Care includes the market leading Kerasal Nail® Fungal
Renewal, clinically proven to improve nail appearance in as little as two weeks
and;  Kerasal® Toe & Foot Anti-Fungal, a highly effective treatment based on
clotrimazole 1%, for foot fungus.  Kerasal Complete Care will be sold in
approximately 7,000 Walgreens locations in the foot care section beginning in
March 2015.

“We are excited to launch our next innovation in foot care. Consistent with our
strategic goal to be number one in products related to nail fungus, we continue
to seek new product innovations that offer unique, convenient and highly
effective solutions for our consumers and retail partners.  Until now, there has
been no product on the market that addresses both these needs, marketed and
promoted as a single convenient solution. Kerasal Complete Care is a dual-pack
kit that provides a daily single regimen for addressing both needs”, said Peter
Wolpert, CEO of Moberg Pharma AB.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 08:30 am (CET) on February 13, 2015.
For additional information contact:
Peter Wolpert, CEO; Phone: +46 (0)70 - 735 71 35; E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Phone: +46 (0)70- 766 60 30; Email: anna.ljung@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
a direct sales and marketing organization in the U.S. and an extensive
distributor network in more than 40 countries. The company’s portfolio includes
the OTC brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and
Fergon®as well as Phase II pipeline assets. Kerasal Nail®(Emtrix®and Nalox™in
certain markets outside the U.S.) is the leading product for the treatment of
nail disorders in the U.S. and Nordic market. The current portfolio will be
supplemented by the acquisition and in-licensing of additional products as well
as product development with a focus on innovative drug delivery of proven
compounds. Moberg Pharma has offices in Stockholm and New Jersey and the
company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX
Nordic Exchange Stockholm. For further information, please visit:
www.mobergpharma.com.